68Ga-citrate PET/MR Imaging for Glioma
This is a prospective, Phase 2, single center, open-label study in adult patients with
presumed WHO grade 3 or 4 glioma who will be undergoing surgical resection as standard of
care. In some cases, patients will have had biopsy. Study participants will undergo
68Ga-citrate PET/MR prior to surgery.